Literature DB >> 12915099

Susceptibility to ovalbumin-induced airway inflammation and fibrosis in inducible nitric oxide synthetase-deficient mice: mechanisms and consequences.

Nicholas J Kenyon1, Kishorchandra Gohil, Jerold A Last.   

Abstract

In a previous study, we showed that BALB/c mice demonstrate significant increases in accumulation of airway collagen after 4 weeks of exposure to ovalbumin aerosol. In the current study we examined the response to ovalbumin aerosol of a different strain of mice, C57BL/6, and compared this response to an otherwise isogenic C57BL strain (iNOS(-/-)) in which the gene for inducible nitric oxide synthetase (iNOS) had been knocked out. We hypothesized that C57BL mice, a Th-1-responsive strain, would be relatively resistant to ovalbumin exposure compared with our previous observations in the BALB/c strain, a Th-2 responder. Our results are consistent with this hypothesis, especially with respect to the accumulation of collagen in the airways of the mice exposed to ovalbumin and increased airway reactivity to challenge with methacholine, as measured by the Penh response. Since NO participates in multiple signal transduction pathways, there was no a priori reason to predict whether iNOS(-/-) mice would be more or less susceptible to allergen-induced airway inflammation than their parental wild-type strain. Responses to ovalbumin exposure of the Th-1-responsive C57BL animals were significantly less (or slower) than those we observed with the iNOS(-/-) mice. Significant increases in airway collagen content were seen only after 6 weeks of exposure of the C57BL mice, as contrasted with 4 weeks in the iNOS(-/-) animals. At each time point examined, Penh values for the iNOS(-/-) mice were significantly increased, while no increases were observed with the C57BL strain. Thus, the iNOS(-/-) mice are more susceptible to ovalbumin-induced airway inflammation and fibrosis than the C57BL strain, giving results intermediate between the previous observations in BALB/c mice and our current findings in C57BL animals with the various assays performed. We also asked whether the effects of knocking out the iNOS gene were exerted before or after the release of TGF-beta(1) by eosinophils and other effector cells in the lung. We measured the response of C57BL and iNOS(-/-) mice to direct intratracheal challenge with TGF-beta(1). There was no apparent response of C57BL mice to TGF-beta(1) at 4 or 11 days after TGF-beta(1) challenge, as evaluated by bronchoprovocation testing. On the other hand, the observed Penh values were significantly greater in iNOS(-/-) mice that had also received TGF-beta(1) 4 days previously. These results strongly support the hypothesis that the increased sensitivity of iNOS(-/-) mice to ovalbumin is at least partially dependent on pathways that come into play subsequent to the release of TGF-beta(1) by effector cells in the lungs of mice exposed to ovalbumin aerosol.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915099     DOI: 10.1016/s0041-008x(03)00227-8

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  12 in total

1.  Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation.

Authors:  Jennifer M Bratt; Kevin Y Chang; Michelle Rabowsky; Lisa M Franzi; Sean P Ott; Simone Filosto; Tzipora Goldkorn; Muhammad Arif; Jerold A Last; Nicholas J Kenyon; Amir A Zeki
Journal:  J Immunol       Date:  2018-04-27       Impact factor: 5.422

2.  (R)-albuterol elicits antiinflammatory effects in human airway epithelial cells via iNOS.

Authors:  Brian N Chorley; Yuehua Li; Shijing Fang; Jin-Ah Park; Kenneth B Adler
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09-29       Impact factor: 6.914

3.  Requirement for inducible nitric oxide synthase in chronic allergen exposure-induced pulmonary fibrosis but not inflammation.

Authors:  Amarjit S Naura; Mourad Zerfaoui; Hogyoung Kim; Zakaria Y Abd Elmageed; Paulo C Rodriguez; Chetan P Hans; Jihang Ju; Youssef Errami; Jiwon Park; Augusto C Ochoa; A Hamid Boulares
Journal:  J Immunol       Date:  2010-07-28       Impact factor: 5.422

4.  Nitric oxide synthase enzymes in the airways of mice exposed to ovalbumin: NOS2 expression is NOS3 dependent.

Authors:  Jennifer M Bratt; Keisha Williams; Michelle F Rabowsky; Michael S Last; Lisa M Franzi; Jerold A Last; Nicholas J Kenyon
Journal:  Mediators Inflamm       Date:  2010-10-05       Impact factor: 4.711

5.  An alpha4beta1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice.

Authors:  Nicholas J Kenyon; Ruiwu Liu; Erin M O'Roark; Wenzhe Huang; Li Peng; Kit S Lam
Journal:  Eur J Pharmacol       Date:  2008-12-13       Impact factor: 4.432

6.  Arginases I and II in lungs of ovalbumin-sensitized mice exposed to ovalbumin: sources and consequences.

Authors:  Nicholas J Kenyon; Jennifer M Bratt; Angela L Linderholm; Michael S Last; Jerold A Last
Journal:  Toxicol Appl Pharmacol       Date:  2008-03-15       Impact factor: 4.219

7.  Role of NOS2 in pulmonary injury and repair in response to bleomycin.

Authors:  Changjiang Guo; Elena Atochina-Vasserman; Helen Abramova; Blessy George; Veleeparambil Manoj; Pamela Scott; Andrew Gow
Journal:  Free Radic Biol Med       Date:  2015-10-23       Impact factor: 7.376

8.  Arginase enzymes in isolated airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin.

Authors:  Jennifer M Bratt; Lisa M Franzi; Angela L Linderholm; Michael S Last; Nicholas J Kenyon; Jerold A Last
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-05       Impact factor: 4.219

9.  Arginase and arginine dysregulation in asthma.

Authors:  Renée C Benson; Karen A Hardy; Claudia R Morris
Journal:  J Allergy (Cairo)       Date:  2011-04-26

10.  Nitric oxide in asthma physiopathology.

Authors:  Carla M Prado; Mílton A Martins; Iolanda F L C Tibério
Journal:  ISRN Allergy       Date:  2011-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.